➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKinsey
Colorcon
Merck
Express Scripts
Dow
Johnson and Johnson

Last Updated: September 17, 2021

DrugPatentWatch Database Preview

Details for Patent: 5,856,336


Email this page to a colleague

« Back to Dashboard

Which drugs does patent 5,856,336 protect, and when does it expire?

Patent 5,856,336 protects LIVALO and is included in one NDA.

Protection for LIVALO has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has ten patent family members in nine countries.

Summary for Patent: 5,856,336
Title: Quinoline type mevalonolactones
Abstract:A compound of the formula ##STR1## Z=--CH(OH)--CH.sub.2 --CH(OH)--CH.sub.2 --COO.1/2Ca have HMG--CoA inhibiting effects, making them useful as inhibitors of cholesterol biosynthesis. The compound may be prepared as a pharmaceutical for reducing hyperlipidemia, hyperlipoproteinemia or atherosclerosis.
Inventor(s): Fujikawa; Yoshihiro (Funabashi, JP), Suzuki; Mikio (Funabashi, JP), Iwasaki; Hiroshi (Funabashi, JP), Sakashita; Mitsuaki (Shiraoka-machi, JP), Kitahara; Masaki (Shiraoka-machi, JP)
Assignee: Nissan Chemical Industries Ltd. (Tokyo, JP)
Application Number:07/883,398
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 5,856,336
Patent Claim Types:
see list of patent claims
Compound; Use;

Drugs Protected by US Patent 5,856,336

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Kowa Co LIVALO pitavastatin calcium TABLET;ORAL 022363-001 Aug 3, 2009 AB RX Yes No ⤷  Try it Free ⤷  Try it Free ⤷  Try it Free
Kowa Co LIVALO pitavastatin calcium TABLET;ORAL 022363-002 Aug 3, 2009 AB RX Yes No ⤷  Try it Free ⤷  Try it Free ⤷  Try it Free
Kowa Co LIVALO pitavastatin calcium TABLET;ORAL 022363-003 Aug 3, 2009 AB RX Yes Yes ⤷  Try it Free ⤷  Try it Free ⤷  Try it Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 5,856,336

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Japan62-207224Aug 20, 1987
Japan63-15585Jan 26, 1988
Japan63-193606Aug 03, 1988

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
McKesson
Express Scripts
Baxter
Harvard Business School
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.